We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Technology Applied for Molecular Testing Outside of Central Laboratories

By LabMedica International staff writers
Posted on 16 Apr 2012
A collaborative program has been initiated to develop assays utilizing the new Discipher system for bringing DNA-based testing and diagnostics to point-of-care settings.

Discipher is a low cost, walk-away system, based on DVD technology. More...
It uses self-contained, disposable assay devices in the form of DVD discs with microfluidic channels. The system was jointly developed by UK-based scientific engineering company Plarion Ltd. (Hertfordshire, UK) and the Scandinavian diagnostics technology development company LingVitae Corporation (Oslo, Norway). This work was supported by funding from the Seventh Research Framework Program of the European Union, under the Digital Sequencing project.

The new research and development collaboration will bring in the Sweden-based technical university KTH Royal Institute of Technology (KTH; Stockholm, Sweden). As part of this engagement, LingVitae/Plarion will transfer prototype versions of the Discipher instrument to the researchers at KTH, as well as support the development work by customizing the optical disc-based disposable assay devices.

“Our aim with Discipher is to democratize molecular and cellular analysis, putting low-cost easy-to-use tools in the hands of the wider community, outside of core laboratories”, said Dr. Jackie Cole, Head of Marketing for Plarion. “We see that the Discipher system addresses an unmet need in bringing DNA-based diagnostics and testing to users who have previously not had access to this technology,” says Prof. Lundeberg, based at the Science for Life Laboratory in Stockholm.

Dr. Preben Lexow, Chief Executive Officer of LingVitae, added, “We look forward to the collaboration with Professor Lundeberg’s group [at KTH]. The track-record of KTH on development of DNA-based assays, utilizing a repertoire of molecular techniques, provides an exciting opportunity for us to expand our activities in the DNA assay space.”

The innovative Discipher system - with its integrated temperature control, centrifuge, and high-resolution readout - is well suited for point-of-care assays requiring minimal end user operation, rapid turnaround times, and ability to multiplex tests. Assay developers, especially in the areas of immune and cellular assays, are encouraged to contact LingVitae to discuss collaborations or assay transfers to the Discipher system.

Related Links:

KTH Royal Institute of Technology
LingVitae Corporation
Plarion Ltd.




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.